What question did this study set out to answer?

To evaluate the prevalence of iron deficiency and its association with risk factors affecting renal dysfunction in chronic kidney disease.

Iron deficiency in patients with the chronic kidney disease: frequency and clinical-prognostic aspects

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates iron deficiency prevalence in chronic kidney disease, suggesting implications for cardiovascular health.

To evaluate the prevalence of iron deficiency and its association with risk factors affecting renal dysfunction in chronic kidney disease.
Included 1,309 patients with chronic kidney disease, aged 16—78 years.
Conducted clinical and laboratory evaluations, assessing iron deficiency by CKD stage and sex.
Performed statistical analyses using Statistica 10.0 and Microsoft Excel.
Iron deficiency prevalence increased from 8.7% at CKD stage C1 to 28.7% at stage C5.
Serum iron levels significantly different: 17.0±7.1 µmol/L in GFR≥60 mL/min vs. 14.8±7.8 µmol/L in GFR<60 mL/min (p<0.001).
Overall prevalence of iron deficiency was 26.8%, with marked gender differences, especially at stages C3A and C5.

Муркамилов et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates iron deficiency prevalence in chronic kidney disease, suggesting implications for cardiovascular health.

To evaluate the prevalence of iron deficiency and its association with risk factors affecting renal dysfunction in chronic kidney disease.
Included 1,309 patients with chronic kidney disease, aged 16—78 years.
Conducted clinical and laboratory evaluations, assessing iron deficiency by CKD stage and sex.
Performed statistical analyses using Statistica 10.0 and Microsoft Excel.
Iron deficiency prevalence increased from 8.7% at CKD stage C1 to 28.7% at stage C5.
Serum iron levels significantly different: 17.0±7.1 µmol/L in GFR≥60 mL/min vs. 14.8±7.8 µmol/L in GFR<60 mL/min (p<0.001).
Overall prevalence of iron deficiency was 26.8%, with marked gender differences, especially at stages C3A and C5.

Муркамилов et al. (2026) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark